(Formerly Chem CHEM 227) Explores the design and enablement of new medicines that were born from a convergence of concepts and techniques from chemistry and biology. Topics include an overview of the drug development process, design of of small molecule medicines with various modes of action, drug metabolism and pharmacogenomics, biologic medicines including protein- and nucleic acid-based therapeutics, glycoscience and glycomimetic drugs, and cell-based medicines derived from synthetic biology. Prerequisite: undergraduate level organic chemistry and biochemistry as well as familiarity with concepts in cell and molecular biology.
3 units · Letter or Credit/No Credit
(Formerly Chem 227) Explores the design and enablement of new medicines that were born from a convergence of concepts and techniques from chemistry and biology. Topics include an overview of the drug development process, design of of small molecule medicines with various modes of action, drug metabolism and pharmacogenomics, biologic medicines including protein- and nucleic acid-based therapeutics, glycoscience and glycomimetic drugs, and cell-based medicines derived from synthetic biology. Prerequisite: undergraduate level organic chemistry and biochemistry as well as familiarity with concepts in cell and molecular biology.
Offered in Spring 2026 at Stanford University.